These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 28376504)
1. Discontinuation/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction. Kane JA; Kim JK; Haidry SA; Salciccioli L; Lazar J Cardiology; 2017; 137(2):121-125. PubMed ID: 28376504 [TBL] [Abstract][Full Text] [Related]
2. Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure. Kim HJ; Jo SH; Lee MH; Seo WW; Choi JO; Ryu KH Adv Ther; 2020 Sep; 37(9):3839-3849. PubMed ID: 32676928 [TBL] [Abstract][Full Text] [Related]
3. Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. Gilstrap LG; Fonarow GC; Desai AS; Liang L; Matsouaka R; DeVore AD; Smith EE; Heidenreich P; Hernandez AF; Yancy CW; Bhatt DL J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28189999 [TBL] [Abstract][Full Text] [Related]
4. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease. Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849 [TBL] [Abstract][Full Text] [Related]
6. Doses of renin-angiotensin system inhibitors but not beta-blockers predict outcome after ST-elevation myocardial infarction. Liu PY; Chen CL; Yu MC; Ko YL; Hsu SY; Chou HH; Yeh KH; Duan DM; Chen MH; Lin JF Acta Clin Belg; 2019 Oct; 74(5):334-341. PubMed ID: 30295167 [No Abstract] [Full Text] [Related]
7. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry. Peri-Okonny PA; Mi X; Khariton Y; Patel KK; Thomas L; Fonarow GC; Sharma PP; Duffy CI; Albert NM; Butler J; Hernandez AF; McCague K; Williams FB; DeVore AD; Patterson JH; Spertus JA JACC Heart Fail; 2019 Apr; 7(4):350-358. PubMed ID: 30738978 [TBL] [Abstract][Full Text] [Related]
8. Addition of angiotensin-converting enzyme inhibitors to beta-blockers has a distinct effect on hispanics compared with african americans and whites with heart failure and reduced ejection fraction: a propensity score-matching study. Eshtehardi P; Pamerla M; Mojadidi MK; Goodman-Meza D; Hovnanians N; Gupta A; Lupercio F; Mazurek JA; Zolty R J Card Fail; 2015 Jun; 21(6):448-56. PubMed ID: 25805065 [TBL] [Abstract][Full Text] [Related]
9. Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure. Bertero E; Miceli R; Lorenzoni A; Balbi M; Ghigliotti G; Chiarella F; Brunelli C; Viazzi F; Pontremoli R; Canepa M; Ameri P Intern Emerg Med; 2019 Oct; 14(7):1083-1090. PubMed ID: 30835055 [TBL] [Abstract][Full Text] [Related]
10. Effect of heart failure pharmacotherapies in patients with heart failure with mildly reduced ejection fraction. Schupp T; Bertsch T; Reinhardt M; Abel N; Schmitt A; Lau F; Abumayyaleh M; Akin M; Weiß C; Weidner K; Behnes M; Akin I Eur J Prev Cardiol; 2024 Aug; 31(11):1347-1360. PubMed ID: 38513366 [TBL] [Abstract][Full Text] [Related]
11. Target Doses of Secondary Prevention Medications Are Not Being Achieved in Patients With Reduced Left Ventricular Ejection Fraction After Acute Coronary Syndrome (ANZACS-QI 34). Chan D; Doughty RN; Lund M; Lee M; Kerr AJ Heart Lung Circ; 2020 Sep; 29(9):1386-1396. PubMed ID: 32423781 [TBL] [Abstract][Full Text] [Related]
12. Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling. Güder G; Störk S; Gelbrich G; Brenner S; Deubner N; Morbach C; Wallenborn J; Berliner D; Ertl G; Angermann CE Eur J Heart Fail; 2015 Apr; 17(4):442-52. PubMed ID: 25727879 [TBL] [Abstract][Full Text] [Related]
13. Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis. Khan MS; Fonarow GC; Ahmed A; Greene SJ; Vaduganathan M; Khan H; Marti C; Gheorghiade M; Butler J Circ Heart Fail; 2017 Aug; 10(8):. PubMed ID: 28790052 [TBL] [Abstract][Full Text] [Related]
14. Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries. Ouwerkerk W; Teng TK; Tromp J; Tay WT; Cleland JG; van Veldhuisen DJ; Dickstein K; Ng LL; Lang CC; Anker SD; Zannad F; Hung CL; Sawhney JPS; Naik A; Shimizu W; Hagiwara N; Wander GS; Anand I; Richards AM; Voors AA; Lam CSP Eur J Heart Fail; 2020 Aug; 22(8):1472-1482. PubMed ID: 32583922 [TBL] [Abstract][Full Text] [Related]
15. Effects of angiotensin receptor blocker at discharge in patients with heart failure with reduced ejection fraction: Korean Acute Heart Failure (KorAHF) registry. Choi KH; Lee GY; Choi JO; Jeon ES; Lee HY; Cho HJ; Lee SE; Kim MS; Kim JJ; Hwang KK; Chae SC; Baek SH; Kang SM; Choi DJ; Yoo BS; Kim KH; Park HY; Cho MC; Oh BH Int J Cardiol; 2018 Apr; 257():168-176. PubMed ID: 29506690 [TBL] [Abstract][Full Text] [Related]
16. Patterns of Use and Clinical Outcomes with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Heart Failure and Changes in Kidney Function: An Analysis of the Veterans' Health Administrative Database. Mathew RO; Lo KB; Tipparaju P; Phelps E; Sidhu MS; Bangalore S; Herzog C; Vaduganathan M; Tang WHW; Rangaswami J Cardiorenal Med; 2021; 11(5-6):226-236. PubMed ID: 34601469 [TBL] [Abstract][Full Text] [Related]
17. Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure. Albert NM; Swindle JP; Buysman EK; Chang C J Am Heart Assoc; 2019 May; 8(9):e011089. PubMed ID: 31023122 [TBL] [Abstract][Full Text] [Related]
18. Implications of renin-angiotensin-system blocker discontinuation in acute decompensated heart failure with systolic dysfunction. Darden D; Drazner MH; Mullens W; Dupont M; Tang WHW; Grodin JL Clin Cardiol; 2019 Oct; 42(10):1010-1018. PubMed ID: 31498919 [TBL] [Abstract][Full Text] [Related]
19. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry. Tomasoni D; Pagnesi M; Colombo G; Chiarito M; Stolfo D; Baldetti L; Lombardi CM; Adamo M; Maggi G; Inciardi RM; Loiacono F; Maccallini M; Villaschi A; Gasparini G; Montella M; Contessi S; Cocianni D; Perotto M; Barone G; Merlo M; Cappelletti AM; Rosano G; Sinagra G; Pini D; Savarese G; Metra M Eur J Heart Fail; 2024 Feb; 26(2):327-337. PubMed ID: 37933210 [TBL] [Abstract][Full Text] [Related]
20. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Heart Failure With Chronic Kidney Disease - Propensity Score Matching Analysis. Kim HJ; Lee MH; Jo SH; Seo WW; Kim SE; Kim KJ; Choi JO; Ahn HS; Choi DJ; Ryu KH Circ J; 2019 Dec; 84(1):83-90. PubMed ID: 31776309 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]